These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 578033)

  • 1. Spectrophotometric determination of factor Xa generation in factor IX concentrates.
    Pepper DS; Banhegyi D; Howie A
    Thromb Haemost; 1977 Jun; 37(3):535-40. PubMed ID: 578033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro thrombogenicity tests of factor IX concentrates. II: effects of phospholipids and heparin.
    Prowse CV; Boffa MC; Guthrie C; Pepper DS
    Thromb Haemost; 1980 Feb; 42(5):1368-77. PubMed ID: 7368144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro thrombogenicity tests of factor IX concentrates. I. A survey of available assays.
    Prowse CV; Chirnside A; Elton RA
    Thromb Haemost; 1980 Feb; 42(5):1355-67. PubMed ID: 6768149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant mechanism of factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis.
    Ishikawa M; Kumashiro M; Yamazaki Y; Atoda H; Morita T
    J Biochem; 2009 Jan; 145(1):123-8. PubMed ID: 18977769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
    Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
    J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro spontaneous thrombin generation in human factor-IX concentrates.
    Sas G; Owens RE; Smith JK; Middleton S; Cash JD
    Br J Haematol; 1975 Sep; 31(1):25-35. PubMed ID: 1212434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated clotting factors in factor IX concentrates.
    Hultin MB
    Blood; 1979 Nov; 54(5):1028-38. PubMed ID: 497395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Simultaneous determination of zymogen activation time and zymogen level using chromogenic substrates in blood coagulation analysis].
    Svendsen L; Brogli M; Stocker K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):150-6. PubMed ID: 6177596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Preparation and clinical use of a new factor IX concentrate].
    Lopaciuk S; Poszwiński P
    Acta Haematol Pol; 1978; 9(2):107-12. PubMed ID: 665130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations.
    Kempton CL; Hoffman M; Roberts HR; Monroe DM
    Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):861-6. PubMed ID: 15653564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombin formation in factor IX concentrates and FEIBA (factor eight inhibitor bypassing activity) (proceedings)].
    Hofmann V; Ermanni M; Straub PW
    Schweiz Med Wochenschr; 1978 Oct; 108(41):1600. PubMed ID: 694497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
    Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
    Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models.
    Prowse CV; Williams AE
    Thromb Haemost; 1980 Oct; 44(2):81-6. PubMed ID: 6779401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of changes in endogenous thrombin potential due to heritable disorders of coagulation.
    Ghosh K; Mota L; Shetty S; Kulkarni B
    Blood Coagul Fibrinolysis; 2008 Sep; 19(6):577-80. PubMed ID: 18685441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Formation of the fibrin clot: the balance of procoagulant and inhibitory factors.
    Lämmle B; Griffin JH
    Clin Haematol; 1985 Jun; 14(2):281-342. PubMed ID: 2994929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential thrombogenicity of factor IX concentrates.
    Snape TJ; Bidwell E
    Thromb Haemost; 1979 Feb; 40(3):571. PubMed ID: 425071
    [No Abstract]   [Full Text] [Related]  

  • 19. Test method for the absence of active clotting factors in dried human blood coagulation factor IX complex.
    Miura Y
    Jpn J Med Sci Biol; 1978; 31(5-6):371-6. PubMed ID: 752738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrochemical activity determination of trypsin-like enzymes. IX. Factor X and Factor Xa in plasma and whole blood.
    Szubarga A; Nigretto JM
    Thromb Res; 1984 Dec; 36(6):647-50. PubMed ID: 6528315
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.